Company intelligence / Profile preview

Immetacyte

Macclesfield, England, United Kingdomir.instilbio.com ↗

Ownership: Private
Development stage: Other

Overview

Immetacyte developed patient-specific immunotherapies using tumor-infiltrating lymphocytes. Its lead program ITIL‑168 entered clinical trials for advanced melanoma but experienced a voluntary pause in the DELTA‑1 trial. The first patient was dosed with ITIL‑306 (engineered TIL using the CoStAR platform) in non-small cell lung cancer. Clinical data from these programs were anticipated in 2023. The company was acquired by Instil Bio and continues development under that brand.

Therapeutic areas: Oncology
Modalities: Cell therapyGene therapy
Industry: Biotech

Partnerships

Academic collaboration with University of Manchester

Beyond the preview

Go deeper on Immetacyte.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immetacyte.

Explore the full profile